血液性恶性瘤患者心血管死亡的时间趋势:20年展望
Gemina Doolub1,2, Avraham Raichman3,4, Dmitry Abramov5
1Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Stoke-on-Trent, UK.
Expert review of cardiovascular therapy
|February 7, 2025
概括
从1999年到2020年,癌症患者的心血管死亡人数下降. 虽然缺血性心脏病仍然很常见,但大多数种族群体的高血压死亡率上升,这表明血液癌症患者心血管风险不断变化.
科学领域:
- 心血管流行病学心血管流行病学
- 血液瘤学 血液瘤学
- 公共卫生研究 公共卫生研究
背景情况:
- 心血管疾病是血液恶性瘤患者的一个重要问题.
- 了解心血管死亡率的趋势对于改善患者的治疗结果至关重要.
研究的目的:
- 分析1999年至2020年美国血液癌症患者心血管相关死亡趋势.
- 通过年龄,性别,种族和血液癌症类型来检查这些趋势.
主要方法:
- 利用多种死因数据库对88146名患有心血管疾病和血液疾病的死者进行了分析.
- 按性别,年龄,种族,拉丁裔起源和血液癌症类型计算的年龄调整后的死亡率.
主要成果:
- 淋巴瘤,白血病和多发性骨髓瘤患者的整体心血管死亡率下降 (-38.8%, -31.8%, -29.4%).
- 缺血性心脏病 (53.4%) 和脑血管疾病 (20.2%) 是导致心血管死亡的主要原因.
- 虽然大多数种族群体的心血管死亡率有所下降,但大多数人的高血压死亡率增加.
结论:
- 在过去二十年中,血液性恶性瘤患者的心血管死亡率有所下降.
- 持续监测和针对高血压等特定心血管风险的有针对性的干预措施是有必要的.
相关概念视频
Hematopoiesis
5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Bone Marrow Sampling and Transplants
277
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
277


